107 related articles for article (PubMed ID: 7998097)
1. Sandimmun neoral, a new oral formulation of cyclosporin A with improved pharmacokinetic characteristics: safety and tolerability in renal transplant patients.
Taesch S; Niese D; Mueller EA
Transplant Proc; 1994 Dec; 26(6):3147-9. PubMed ID: 7998097
[No Abstract] [Full Text] [Related]
2. Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
Offermann G; Korn A
Transplant Proc; 1996 Aug; 28(4):2204-6. PubMed ID: 8769201
[No Abstract] [Full Text] [Related]
3. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
Taesch S; Niese D
Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience in transferring kidney transplant patients from sandimmun to sandimmun neoral--results after 6 months.
Neumayer HH; Färber L; Haller P; Kohnen R; Maibücher A; Schuster A; Vollmar J; Waiser J
Transplant Proc; 1995 Oct; 27(5):2679-82. PubMed ID: 7482873
[No Abstract] [Full Text] [Related]
5. Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
Buchholz B; Korn A
Transplant Proc; 1996 Aug; 28(4):2187-8. PubMed ID: 8769195
[No Abstract] [Full Text] [Related]
6. A study to assess the efficacy, tolerability, and safety of a new oral formulation of Sandimmun--Sandimmun Neoral--in stable renal transplant patients.
Rosental R; Bicans J; Berzina R; Zezina L
Transplant Proc; 1995 Dec; 27(6):3436-7. PubMed ID: 8540038
[No Abstract] [Full Text] [Related]
7. Cyclosporine pharmacokinetic profiles in stable renal allograft recipients converting from Sandimmun to Neoral.
Vathsala A; Lee WT; Jacob E; Woo KT
Transplant Proc; 1996 Jun; 28(3):1324-6. PubMed ID: 8658678
[No Abstract] [Full Text] [Related]
8. The Neoral formulation: improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients.
Kahan BD; Dunn J; Fitts C; Van Buren D; Wombolt D; Pollak R; Carson R; Alexander JW; Chang C; Choc M
Transplant Proc; 1994 Oct; 26(5):2940-3. PubMed ID: 7940928
[No Abstract] [Full Text] [Related]
9. Use of Sandimmun Neoral in renal transplant patients. International Sandimmun Neoral Study Group.
Frei U; Taesch S; Niese D
Transplant Proc; 1994 Oct; 26(5):2928-31. PubMed ID: 7940925
[No Abstract] [Full Text] [Related]
10. A randomized, controlled, double-blind study of the safety and tolerability of Sandimmun Neoral in stable renal transplant patients. Argentine Multicentre Study Group.
Massari PU; Grosso S; de Boccardo G; Vásquez MC; Schiavelli RO; Sabbatiello RR; Casadei DH; Rial MC; Jost LJ; Túrin MD; Agost Carreño C A; Maggiora EC; Gadea MM
Transplant Proc; 1996 Dec; 28(6):3365-7. PubMed ID: 8962310
[No Abstract] [Full Text] [Related]
11. Conversion from conventional Sandimmun to Neoral therapy in stable renal transplant recipients.
Løkkegaard H; Asmundsson P; Clausen P; Dieperink H; Hansen JM; Heaf J; Jensen SB; Kornerup HJ; Madsen S; Pedersen EB; Poulsen JV; Rasmussen K
Transplant Proc; 1996 Aug; 28(4):2199-201. PubMed ID: 8769199
[No Abstract] [Full Text] [Related]
12. Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
Tsang WK; Ho YW; Tong KL; Chan WH; Chan A
Transplant Proc; 1996 Jun; 28(3):1330-2. PubMed ID: 8658681
[No Abstract] [Full Text] [Related]
13. Experience with clinical use of Sandimmun Neoral in renal transplant patients.
Min ZL; Zhao M; Zhu YH; Qi J; Wang LM; Wang YW
Transplant Proc; 1996 Jun; 28(3):1356-7. PubMed ID: 8658692
[No Abstract] [Full Text] [Related]
14. Evaluation of the new cyclosporine formulation, Consupren, in renal transplant patients.
Stephan AG; Barbari A; Masri MA; Rizk S; Moubarak R; Frem GJ; Kamel G; Baracat-Khoury W; Karam A
Transplant Proc; 1996 Jun; 28(3):1348-9. PubMed ID: 8658688
[No Abstract] [Full Text] [Related]
15. Sandimmun neoral pharmacokinetics: impact of the new oral formulation.
Holt DW; Mueller EA; Kovarik JM; van Bree JB; Richard F; Kutz K
Transplant Proc; 1995 Feb; 27(1):1434-7. PubMed ID: 7878935
[No Abstract] [Full Text] [Related]
16. Case study: de novo application of Neoral in renal transplantation.
Kahan BD
Transplant Proc; 1996 Aug; 28(4):2189-91; discussion 2192, 2195. PubMed ID: 8769196
[No Abstract] [Full Text] [Related]
17. Six-month clinical outcome of cyclosporine microemulsion formulation (Sigmasporin Microral) in stable renal transplant patients previously maintained on sandimmun neoral.
Al Wakeel JS; Shaheen FA; Mathew MC; Abou Zeinab HM; Al Alfi A; Tarif NM; Al Mousawi MS; Mahmoud TS; Alorrayed AS; Fagir EA; Dham RS; Shaker DS
Transplant Proc; 2008 Sep; 40(7):2245-51. PubMed ID: 18790205
[TBL] [Abstract][Full Text] [Related]
18. [Variability of the bioavailability of cyclosporine: benefit of the Neoral formulation].
Humbert H
Therapie; 1997; 52(4):353-7. PubMed ID: 9437891
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of conversion from once daily Sandimmun to twice daily Neoral cyclosporine in renal allograft recipients.
Vathsala A; Lee WT; Lu YM; Woo KT
Transplant Proc; 1998 Aug; 30(5):1746-8. PubMed ID: 9723264
[No Abstract] [Full Text] [Related]
20. Comparison of the pharmacokinetics of cyclosporine Sandimmune with Sandimmune Neoral in stable renal transplant patients.
Sketris IS; Lawen JG; Beauregard-Zollinger L; Belitsky P; Landsberg D; Givner ML; Keown P
Transplant Proc; 1994 Oct; 26(5):2961-3. PubMed ID: 7940935
[No Abstract] [Full Text] [Related]
[Next] [New Search]
